

**Media Contact:**  
Garrett D. Smith  
Phone: 240.238.4900  
gsmith@accelovance.com

## **Accelovance Nominated for Vaccine Industry Excellence Award**

Rockville, MD – April 7, 2008 – Accelovance is recognized for its impact on the vaccine industry; presenting customized and strategic clinical solutions for vaccine development programs. The upcoming World Vaccine Congress has named Accelovance as a finalist in the awards category “Best Contract Research Organization” at the inaugural Vaccine Industry Excellence (ViE) Awards reception. The ViE Awards honor and generate public recognition of the efforts, accomplishments and positive contributions of organizations and individuals in the global vaccine industry.

Over the years, Accelovance’s approach to optimizing productivity in clinical research has demonstrated impressive results in vaccine clinical programs. Sponsors have seen their programs executed with greater control, predictability, assurance and quality than originally anticipated. “It is a great honor to receive recognition for our commitment to improving the way vaccine clinical programs are executed. A testament to the value Accelovance brings clients through a customized service offering,” commented an enthusiastic Stephen J. Trevisan, President and CEO.

Accelovance leverages its flexible CRO services, wholly-owned and research dedicated clinical sites, and proactive patient recruitment to drive high volume enrollment in reduced timelines and quality execution. Chief Scientific Officer, Robert C. deGroof, PhD remarked, “Our clients have valued our focus and dedication. This nomination adds credibility to our innovative approach.”

The awards will be judged by an independent panel of experts whose mission is to identify and reward those companies and individuals who have demonstrated an unparalleled ability to succeed, continually set standards of excellence and those destined to be the future stars of the vaccine industry. The ViE Awards ceremony and gala dinner will be held on April 22, 2008 during the annual World Vaccine Congress in Washington, DC.

Headquartered in Rockville, Maryland, Accelovance is a privately held company that has developed a unique system for delivering quality, on time, and cost effective clinical studies. In China, the Company operates through its wholly-owned foreign enterprise in Beijing as a contract research organization (CRO). Accelovance is focused on optimizing the quality and productivity of multiple clinical sites, through strong central management and targeted pro-active patient recruitment. Delivering high quality and timely clinical trial support services, Accelovance is committed to understanding and meeting its clients needs to contribute to their success.

For more information, visit the company’s website at <http://www.accelovance.com>.